Paris – Biosystems International (BSI), a biotechnology company

specializing in the discovery of novel monoclonal antibody based diagnostics, announces its

merger with the company MicroBioChips (MBC) by contribution of assets.

Advantages of the merger

Following a successful partnership to develop monoclonal antibody microarrays, in which BSI

provided the antibodies and MBC produced and commercialized the microarrays, the two

companies have decided to solidify their collaboration by merging their activities. By combining

their collective expertise the resulting company will optimize the production and sales of

microarrays and related services and accelerate the development of diagnostic tests by BSI. In

addition, the merger will lead to significant commercial, administrative and financial synergies.

“The merger of BSI and MBC is not limited to synergies and cost savings. Our complimentary

business cultures will profoundly change our way of doing business, reducing the time to market

for our diagnostics including in the short-term our test for lung cancer which is in late

development,” said Jean Pierre Tirouflet, President of Biosystems International.

Conditions of the merger

The partial transfer of assets of MBC to BSI was approved in Shareholders meetings held by the

two companies at the end of July, 2010. Preceding the transaction, the two companies realized a

capital increase of 2 125 000 € ($2 750 000) for BSI and 225 000 € ($300 000) for MBC assuring the

new merged company sufficient capital for future development.

MBC

Microbiochips is a company specialized in the production of protein and antibody arrays and

related services. Certified ISO 9001, the company excels in the custom production and

processing of protein microarrays, bioinformatics and data analysis for academic and industrial

clients including major pharmaceutical companies.